Pulmonx Corporation (LUNG)

6,17 +0,03 (+0,49%) Al cierre: 04:00PM EDT

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063
United States
650 364 0400
https://pulmonx.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 279

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. David A. Lehman	General Counsel & Secretary	651,39k	N/A	1961
Mr. Geoffrey Beran Rose	Chief Commercial Officer	632,29k	N/A	1974
Mr. Steven S. Williamson	CEO, President & Director	N/A	N/A	1973
Mr. Mehul Joshi	Chief Financial Officer	N/A	N/A	1961
Mr. Sri Radhakrishnan	Chief Technical Officer	N/A	N/A	N/A
Ms. Marcee M. Maroney	Vice President of Marketing	N/A	N/A	1970
Sarah Huber	Vice President of Sales (U.S.)	N/A	N/A	N/A
Ms. Lisa Paul	Chief People Officer	N/A	N/A	1964
Mr. Jérôme Erath	Senior VP & GM of Europe Middle-East & Africa	N/A	N/A	N/A
Mr. John B. McKune	VP & Corporate Controller	N/A	N/A	1976

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Gobierno corporativo

El ISS Governance QualityScore de Pulmonx Corporation, a día 1 de junio de 2024, es 10. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.